This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?
This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.
This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.
This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…
El síndrome nefrótico en niños puede implicar recaídas frecuentes, alta carga de esteroides y decisiones terapéuticas difíciles. Entonces, ¿cuál mantiene mejor la remisión: tacrolimus o micofenolato de mofetilo?
Revisa el VA y únete a la discusión en #NephJC
Nephrotic syndrome in kids can mean frequent relapses, high steroid burden, and tough treatment choices. So which helps maintain remission better: Tacrolimus or MMF?
See the Visual Abstract Krithika Mohan
Nephrotic syndrome in children, especially those with frequent relapses or steroid dependence, remains a therapeutic challenge. The STAMP trial compared tacrolimus and mycophenolate mofetil to help guide treatment decisions.
Can we train to deal with the pain? HOPE trial shows us that non-pharmacological intervention can be an option. Visual abstract by Cristina Popa
Check out the dreamy Visual Abstract by Cristina Popa
Any sleep potion for insomnia in patients on hemodialysis?
